Abiraterone oral - Bukwang Pharmaceuticals
Alternative Names: SOL-804Latest Information Update: 28 Nov 2024
At a glance
- Originator Solural Pharma
- Developer Bukwang Pharmaceutical; Solural Pharma
- Class Antiandrogens; Antineoplastics; Phenanthrenes; Pyridines; Small molecules
- Mechanism of Action CYP17A1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Prostate cancer
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for phase-I development in Prostate-cancer(Hormone refractory, Metastatic disease) in South Korea (PO)
- 25 Feb 2022 Bukwang Pharmaceuticals completes a phase-I trial in Prostate cancer (Metastatic disease, Hormone refractory) in South Korea (PO)
- 21 Oct 2021 Phase-I clinical trials in Prostate cancer (Metastatic disease, Hormone refractory) in South Korea (PO)